The survey contains 26 items distributed across the following domains: demographic characteristics, GLP-1 agonist use and clinical information, smoking status and behaviors, nicotine craving and perceived changes in craving following GLP-1 use, exposure to secondhand smoke, and treatment-related side effects
PMID 1330133
Ozempic, which contains semaglutide GLP-1, is primarily used for blood sugar control in type 2 diabetes patients but also has significant weight loss benefits
The addition of glycine and vitamin B12 is intended to support patients experiencing issues such as fatigue, muscle loss, or neuropathycommon concerns during weight loss or diabetes treatmentand may offer metabolic, neurological, and musculoskeletal benefits
While medication provides the initial weight loss, sustainable lifestyle changes determine whether results persist after discontinuation
Finally, we discuss health inequities in obesity, the dangers of perpetuating these inequities if GLP-1RA access remains biased, and the opportunities for improvement [46]
